期刊
BRITISH JOURNAL OF PSYCHIATRY
卷 199, 期 4, 页码 275-280出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjp.bp.110.083907
关键词
-
类别
资金
- Government of Canada
- Japanese Society of Clinical Neuropsychopharmacology
- Kanae Foundation
- Mochida Memorial Foundation
- Dainippon Sumitomo Pharma
- Kyowa Hakko Kirin
- Schizophrenia Society of Ontario
- Canadian Diabetes Association
- Novartis Canada
- Medicure
- Canadian Institutes of Health Research
- Canadian Psychiatric Research Foundation
- Pfizer
- CanAm Bioresearch
- Novartis
- Pfizer Health Research Foundation
- GlaxoSmithKline
- Otsuka Pharmaceutical
- Janssen Pharmaceutical
- Abbott Laboratories
- Janssen-Cilag
- Lilly
- Bristol-Myers Squibb
Background Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia. Aims To address the early time-line for improvement with antipsychotics in treatment-resistant schizophrenia. Method Randomised double-blind trials of antipsychotic medication in adult patients with treatment-resistant schizophrenia were investigated (last search June 2010). A series of meta-regression analyses were carried out to examine the effect of time on the average item scores in the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) at three or more distinct time points within the first 6 weeks of treatment. Results Study duration varied from 4 weeks to 1 year and the definitions of treatment resistance as well as of treatment response were not necessarily consistent across 19 identified studies, resulting in highly variable rates of response (0-76%). The mean standardised baseline item score in the PANSS or BPRS was 3.4 (s.e.=0.06) in the five studies included in the meta-regression analysis, with the average baseline Clinical Global Impression - Severity score being 5.2 (marked illness). For the pooled population treated with a range of antipsychotics (n = 1019), significant reductions in the mean item scores occurred during the first 4 weeks; improvements observed in later weeks were smaller and non-significant. In contrast, weekly improvement with clozapine was significant throughout (n = 356). Conclusions Our findings provide preliminary evidence that ::he majority of improvement with antipsychotics may occur relatively early. More consistent improvements with clozapine may be associated with a gradual titration. To further elucidate response patterns, future studies are needed to provide data over regular intervals during earlier stages of treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据